Healthcare provider profile · identity verified

Falguni Doshi, MD

Internal Medicine · ANAHEIM, CA · NPI 1336210236

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	747	248
Amlodipine Besylate	Amlodipine Besylate	363	123
Levothyroxine Sodium	Levothyroxine Sodium	293	95
Atenolol	Atenolol	245	75
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	236	75
Omeprazole	Omeprazole	207	77
Gabapentin	Gabapentin	198	77
Simvastatin	Simvastatin	190	61
Lisinopril	Lisinopril	184	62
Rosuvastatin Calcium	Rosuvastatin Calcium	161	58
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	155	32
Meloxicam	Meloxicam	152	56
Metformin Hcl	Metformin Hcl	152	48
Losartan Potassium	Losartan Potassium	147	52
Alendronate Sodium	Alendronate Sodium	145	49
Glipizide	Glipizide	138	42
Metformin Hcl Er	Metformin Hcl	121	48
Trazodone Hcl	Trazodone Hcl	120	30
Pantoprazole Sodium	Pantoprazole Sodium	113	37
Acetaminophen-Codeine	Acetaminophen With Codeine	98	22
Albuterol Sulfate Hfa	Albuterol Sulfate	97	45
Sertraline Hcl	Sertraline Hcl	97	28
Potassium Chloride	Potassium Chloride	93	38
Terazosin Hcl	Terazosin Hcl	90	30
Furosemide	Furosemide	72	37
Prednisone	Prednisone	72	65
Humulin N	Insulin Nph Human Isophane	71	20
Famotidine	Famotidine	69	29
Hydrochlorothiazide	Hydrochlorothiazide	69	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	68	24
Duloxetine Hcl	Duloxetine Hcl	66	19
Jardiance	Empagliflozin	64	21
Tamsulosin Hcl	Tamsulosin Hcl	64	20
Pradaxa	Dabigatran Etexilate Mesylate	63	21
Metoprolol Tartrate	Metoprolol Tartrate	62	20
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	56	50
Fluoxetine Hcl	Fluoxetine Hcl	55	17
Bisoprolol Fumarate	Bisoprolol Fumarate	54	19
Tramadol Hcl	Tramadol Hcl	52	14
Triamcinolone Acetonide	Triamcinolone Acetonide	48	37
Clopidogrel	Clopidogrel Bisulfate	47	16
Azithromycin	Azithromycin	45	44
Donepezil Hcl	Donepezil Hcl	45	15
Finasteride	Finasteride	38	14
Bupropion Xl	Bupropion Hcl	37	12
Cephalexin	Cephalexin	37	28
Allopurinol	Allopurinol	36	12
Citalopram Hbr	Citalopram Hydrobromide	35	15
Trospium Chloride	Trospium Chloride	34	suppressed
Eliquis	Apixaban	33	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	30
Carvedilol	Carvedilol	31	11
Alprazolam	Alprazolam	30	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Estradiol	Estradiol	29	16
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Latanoprost	Latanoprost	28	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	28	11
Clonazepam	Clonazepam	26	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Humulin R	Insulin Regular, Human	26	suppressed
Ibuprofen	Ibuprofen	26	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Temazepam	Temazepam	25	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	24	22
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Atovaquone-Proguanil Hcl	Atovaquone/Proguanil Hcl	23	23
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Ozempic	Semaglutide	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	20
Clobetasol Propionate	Clobetasol Propionate	22	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	22	21
Spironolactone	Spironolactone	22	suppressed
Fluocinonide	Fluocinonide	21	suppressed
Ketoconazole	Ketoconazole	21	12
Montelukast Sodium	Montelukast Sodium	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Metoprolol Succinate	Metoprolol Succinate	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	17	suppressed
Alvesco	Ciclesonide	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Mupirocin	Mupirocin	16	14
Nitroglycerin	Nitroglycerin	16	suppressed
Ofloxacin	Ofloxacin	16	16
Verapamil Er	Verapamil Hcl	16	suppressed
Digoxin	Digoxin	15	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	15	suppressed
Topiramate	Topiramate	15	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	15	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Colchicine	Colchicine	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Ciclopirox	Ciclopirox	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Naproxen	Naproxen	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error